e-Therapeutics’ ETS2101 enters phase I clinical trial in brain cancer
Led by Professor Santosh Kesari, MD, PhD, director of neuro-oncology at the UC San Diego Moores Cancer Center in La Jolla, California, the trial will enrol up to 24 patients. Successive cohorts of patients will receive increasing doses of ETS2101. The primary objective is to evaluate safety and determine an appropriate dose for phase II development. Secondary objectives include initial assessment of the drug’s activity, detailed study of its distribution within the brain and investigation of potential biomarkers of response. First findings are expected in late 2012 and final results during 2013.
The brain cancer trial is one of two studies in the phase I programme for ETS2101. A second, larger trial will start shortly in the UK and will evaluate the drug in patients with a wide variety of tumour types. The decision to support a focused brain cancer trial in parallel with a broader phase I study reflects the particularly interesting data obtained from work with glioma cell lines and the ability of ETS2101, unlike many current cancer drugs, to cross the blood-brain barrier.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.